drugset
drugset / Trial / NCT00638898

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

NCT00638898 ↗

Phase 1 Completed 25 enrolled City of Hope Medical Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This clinical trial is studying how well giving busulfan, melphalan, and topotecan hydrochloride together with a stem cell transplant works in treating patients with newly diagnosed or relapsed solid tumor.

Timeline

Start
2007-02-26
Primary completion
2013-01-19
Completion
2024-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule — Intravenous
Subject Melphalan Small molecule — Intravenous
Subject Topotecan Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Intravenous

Indications

Ewing sarcoma adult central nervous system germ cell tumor cancer of unknown primary site childhood brain stem glioma childhood central nervous system germ cell tumor childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood ependymoma childhood medulloblastoma extragonadal nonseminomatous germ cell tumor kidney cancer malignant childhood germ cell neoplasm malignant testicular germ cell tumor neuroblastoma optic pathway glioma ovarian mixed germ cell neoplasm pineoblastoma rhabdomyosarcoma supratentorial primitive neuroectodermal tumor